Dapoxetine
Also known as: Priligy, Westoxetin
SSRI | Premature Ejaculation Treatment
Overview
Dapoxetine is the first and only selective serotonin reuptake inhibitor (SSRI) specifically developed and approved for the on-demand treatment of premature ejaculation (PE) in men aged 18-64. Unlike conventional SSRIs such as paroxetine or sertraline -- which are sometimes used off-label for PE but require daily dosing and weeks to reach therapeutic effect -- dapoxetine was engineered for rapid absorption and short elimination, making it suitable for as-needed use 1-3 hours before sexual activity. Originally developed by Eli Lilly and later licensed to Johnson & Johnson (ALZA Corporation), dapoxetine received its first regulatory approval in Sweden in 2009 under the brand name Priligy, and has since been approved in over 50 countries across Europe, Asia, Latin America, and the Middle East. It has not received FDA approval in the United States despite multiple submissions. Dapoxetine works by increasing serotonin activity at the postsynaptic cleft in the ejaculatory reflex pathway, raising the threshold for ejaculation and improving control over the timing of climax.
Key benefits
- Only SSRI specifically developed for on-demand premature ejaculation treatment
- Rapid onset of action (1-2 hours) allows as-needed dosing before sexual activity
- Ultra-short half-life (~1.5 hours) minimizes sustained serotonergic side effects
- Clinically proven to increase intravaginal ejaculatory latency time (IELT) by 2-3 fold
- Improves perceived control over ejaculation and reduces PE-related distress
- Does not require daily dosing or washout periods
- Well-studied safety profile across multiple international clinical trials
- Approved in over 50 countries for on-demand PE treatment
Mechanism of action
Dapoxetine selectively inhibits the serotonin transporter (SERT) at presynaptic nerve terminals, blocking reuptake of serotonin (5-HT) from the synaptic cleft. This increases serotonin concentration at postsynaptic receptors in the neural circuits governing the ejaculatory reflex, particularly within the spinal ejaculation generator and supraspinal pathways. The ejaculatory process is modulated by serotonergic neurotransmission: higher serotonin levels at 5-HT1B and 5-HT2C receptors raise the ejaculatory threshold, delaying the emission and expulsion phases of ejaculation. Unlike traditional SSRIs that require 1-2 weeks of daily dosing to achieve steady-state serotonin levels, dapoxetine reaches peak plasma concentration within approximately 1-2 hours after oral administration and is rapidly eliminated (terminal half-life ~1.5 hours, with an initial half-life of ~1.4 hours). This pharmacokinetic profile enables acute, on-demand modulation of serotonergic tone without the sustained receptor desensitization seen with chronic SSRI use.
Molecular data
- Type
- Short-acting selective serotonin reuptake inhibitor (SSRI)
- Half-life
- ~1.5 hours
Indications
What the research community uses this compound for, with self-reported effectiveness.
Sexual Health
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 30mg | As needed, 1-3 hours before sexual activity | — |
| — | 60mg | As needed, 1-3 hours before sexual activity | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea (11-22%, most common side effect, usually mild and transient)
- Dizziness (5-11%)
- Headache (5-9%)
- Diarrhea (3-7%)
- Insomnia (2-4%)
- Fatigue (2-4%)
- Somnolence (2-3%)
- Dry mouth (1-2%)
Rare side effects
- Syncope or pre-syncope (vasovagal) -- reported in approximately 0.1-0.3% of patients, usually preceded by prodromal symptoms (nausea, dizziness, lightheadedness)
- Orthostatic hypotension
- Serotonin syndrome (when combined with other serotonergic agents)
- Suicidal ideation (class warning for SSRIs, though risk is considered very low with on-demand dosing)
- Seizures (very rare)
- Mania or hypomania in individuals with undiagnosed bipolar disorder
Contraindications
- Concurrent use of SSRIs, SNRIs, MAOIs, tricyclic antidepressants, or other serotonergic medications
- Use within 14 days of stopping an MAOI or serotonergic antidepressant
- Significant cardiac conditions: heart failure (NYHA Class II-IV), conduction abnormalities (second or third degree AV block), ischemic heart disease, significant valvular disease
- History of syncope or orthostatic hypotension
- Moderate to severe hepatic impairment (Child-Pugh Class B or C)
- Known hypersensitivity to dapoxetine or any excipient
- Concurrent use of potent CYP3A4 inhibitors at the 60mg dose
- Patients under 18 or over 65 years of age (limited safety data)
References
Primary literature and clinical-trial data informing this entry.